NCT04704934: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Sponsor: Daiichi Sankyo. Phase: PHASE3. Conditions: Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma